Effects of novel lactoferrin peptides on LPS ‐induced alveolar bone destruction in a rat model
Chemical Biology & Drug Design · 2024
DOI: 10.1111/cbdd.14574 ↗At a glance
Journal article in Chemical Biology & Drug Design, 2024. Written by Sakura Yamada and 8 co-authors. Institution: Department of Oral and Maxillofacial Pathobiology, Graduate School of Biomedical and Health Sciences, Hiroshima University, Hiroshima, Japan. Major MEDLINE topics: Lactoferrin, Lipopolysaccharides, Peptides, Osteoclasts. Cited 7 times so far (Crossref); 33 references. The full text is freely available (open access, CC BY-NC-ND 4.0).
Abstract (original language)
To develop novel bovine lactoferrin (bLF) peptides targeting bLF‐tumour necrosis factor (TNF) receptor‐associated factor 6 (TRAF6) binding sites, we identified two peptides that could target bLF‐TRAF6 binding sites using structural analysis. Moreover, another peptide that could bind to the TRAF6 dimerization area was selected from the bLF sequence. The effects of each peptide on cytokine expression in lipopolysaccharide (LPS)‐stimulated osteoblasts (ST2) and on osteoclastogenesis were examined using an LPS‐treated co‐culture of primary bone marrow cells (BMCs) with ST2 cells and a single culture of osteoclast precursor cells (RAW‐D) treated with soluble receptor activator of NF‐κB ligand. Finally, the effectiveness of these peptides against LPS‐induced alveolar bone destruction was assessed. Two of the three peptides significantly suppressed LPS‐induced TNF‐α and interleukin‐1β expression in ST2 cells. Additionally, these peptides inhibited and reversed LPS‐induced receptor activator of NF‐κB ligand (RANKL) upregulation and osteoprotegerin (OPG) downregulation, respectively. Furthermore, both peptides significantly reduced LPS‐induced osteoclastogenesis in the BMC‐ST2 co‐culture and RANKL‐induced osteoclastogenesis in RAW‐D cells. In vivo, topical application of these peptides significantly reduced the osteoclast number by downregulating RANKL and upregulating OPG in the periodontal ligament. It is indicated that the novel bLF peptides can be used to treat periodontitis‐associated bone destruction.
Subjects
MeSH terms (MEDLINE)
Author keywords
Substances
Authors and institutions
- Department of Oral and Maxillofacial Pathobiology, Graduate School of Biomedical and Health Sciences, Hiroshima University, Hiroshima, Japan.
- Department of Orthodontics and Craniofacial Developmental Biology, Graduate School of Biomedical and Health Sciences, Hiroshima University, Hiroshima, Japan.
- Faculty of Dentistry, University of Puthisastra, Phnom Penh, Cambodia.
- Collaborative Research Laboratory of Oral Inflammation Regulation, Graduate School of Biomedical and Health Science, Hiroshima University, Hiroshima, Japan.
- Laboratory of Molecular Biophysics, Graduate School of Integrated Sciences for Life, Hiroshima University, Hiroshima, Japan.
- SKCM2, Hiroshima University, Hiroshima, Japan.
Cite
APA
Yamada, S., Chea, C., Furusho, H., Oda, K., Shiba, F., Tanimoto, K., Tate, S. I., Miyauchi, M., & Takata, T. (2024). Effects of novel lactoferrin peptides on LPS ‐induced alveolar bone destruction in a rat model. Chemical Biology & Drug Design. https://doi.org/10.1111/cbdd.14574
Vancouver
Yamada S, Chea C, Furusho H, Oda K, Shiba F, Tanimoto K, et al. Effects of novel lactoferrin peptides on LPS ‐induced alveolar bone destruction in a rat model. Chemical Biology & Drug Design. 2024. doi:10.1111/cbdd.14574
BibTeX
@article{Yamada2024,
author = {Yamada, Sakura and Chea, Chanbora and Furusho, Hisako and Oda, Kanae and Shiba, Fumie and Tanimoto, Kotaro and Tate, Shin-Ichi and Miyauchi, Mutsumi and Takata, Takashi},
title = {Effects of novel lactoferrin peptides on LPS ‐induced alveolar bone destruction in a rat model},
journal = {Chemical Biology & Drug Design},
year = {2024},
doi = {10.1111/cbdd.14574}
}
EUVIMED